Abstract
Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomorphine. Preclamol had a mild but unequivocal antiakinetic effect, less than that caused by subcutaneous apomorphine, but it provoked less dyskinesia. Further studies to explore the therapeutic potential of preclamol seem justified.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Antiparkinson Agents / administration & dosage
-
Antiparkinson Agents / therapeutic use*
-
Apomorphine / administration & dosage
-
Apomorphine / pharmacology
-
Blood Pressure / drug effects
-
Dopamine Agonists / administration & dosage
-
Dopamine Agonists / pharmacology
-
Female
-
Humans
-
Injections, Subcutaneous
-
Male
-
Middle Aged
-
Movement / drug effects
-
Parkinson Disease / drug therapy*
-
Piperidines / administration & dosage
-
Piperidines / therapeutic use*
-
Receptors, Dopamine D1 / agonists
-
Receptors, Dopamine D2 / agonists
Substances
-
Antiparkinson Agents
-
Dopamine Agonists
-
Piperidines
-
Receptors, Dopamine D1
-
Receptors, Dopamine D2
-
preclamol
-
Apomorphine